

1 **Pre-existing antibodies targeting a linear epitope on**
2 **SARS-CoV-2 S2 cross-reacted with commensal gut bacteria**
3 **and shaped vaccine induced immunity**

4 Liqu Jia^{1, §}, Shufeng Weng^{2, §}, Jing Wu^{1, §}, Xiangxiang Tian^{3, 4}, Yifan Zhang^{3, 4},
5 Xuyang Wang¹, Jing Wang^{3, 5}, Dongmei Yan⁵, Wanhai Wang⁴, Fang Fang³,
6 Zhaoqin Zhu^{3, #}, Chao Qiu^{6, #}, Wenhong Zhang^{1, 2, 7, 8, #}, Ying Xu^{2, #}, Yanmin
7 Wan^{1, 2, 9, #}

8

9 ¹ Department of Infectious Diseases, National Medical Center for Infectious Diseases,
10 Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response,
11 Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China;

12 ² State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life
13 Science, Fudan University, Shanghai, China;

14 ³ Shanghai Public Health Clinical Center, Fudan University, Shanghai, China;

15 ⁴ Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Key Laboratory
16 of Laboratory Medicine of Henan Province, Zhengzhou, Henan, P.R. China;

17 ⁵ Department of Immunology, School of Basic Medical, Jiamusi University, Jiamusi,
18 Heilongjiang Province, China;

19 ⁶ Institutes of biomedical sciences & Shanghai Key Laboratory of Medical Epigenetics,
20 Fudan University, Shanghai, China;

21 ⁷ National Clinical Research Center for Aging and Medicine, Huashan Hospital, Shanghai
22 Medical College, Fudan University, Shanghai, China;

23 ⁸ Key Laboratory of Medical Molecular Virology (MOE/MOH) and Institutes of Biomedical
24 Sciences, Shanghai Medical College, Fudan University, Shanghai, China.

25 ⁹ Department of radiology, Shanghai Public Health Clinical Center, Shanghai, China

26 § These authors contribute equally to this work.

27 # Correspondence should be addressed to: Zhaoqin Zhu, zhaqinzh@163.com; Chao
28 Qiu, qiuchao@fudan.edu.cn; Wenhong Zhang, zhangwenhong@fudan.edu.cn; Ying Xu,
29 yingxu2520@fudan.edu.cn; Yanmin Wan, yanmin_wan@fudan.edu.cn

30

31 **Running title:** SARS-CoV-2 antibody cross-reacts with gut bacteria

32 **Word count:** Abstract, 196; main text, 6810

33

34 **Abstract**

35 The origins of pre-existing SARS-CoV-2 cross-reactive antibodies and their
36 potential impacts on vaccine efficacy have not been fully clarified. In this study,
37 we demonstrated that S2 was the prevailing target of the pre-existing S protein
38 cross-reactive antibodies in both healthy human and SPF mice. A dominant
39 antibody epitope was identified on the connector domain of S2
40 (1147-SFKEELDKYFKNHT-1160, P144), which could be recognized by
41 pre-existing antibodies in both human and mouse. Through metagenomic
42 sequencing and fecal bacteria transplant, we proved that the generation of S2
43 cross-reactive antibodies was associated with commensal gut bacteria.
44 Furthermore, six P144 specific monoclonal antibodies were isolated from
45 naïve SPF mice and proved to cross-react with commensal gut bacteria
46 collected from both human and mouse. Mice with high levels of pre-existing S2
47 cross-reactive antibodies mounted higher S protein specific binding antibodies,
48 especially against S2, after being immunized with a SARS-CoV-2 S DNA
49 vaccine. Similarly, we found that levels of pre-existing S2 and P144 reactive
50 antibodies correlated positively with RBD specific binding antibody titers after
51 two doses of inactivated SARS-CoV-2 vaccination in human. Finally, we
52 provided data demonstrating that immunization of a SARS-CoV-2 S DNA
53 vaccine could alter the gut microbiota compositions of mice.

54

55

56 **Key words:** Cross-reactive antibody, SARS-CoV-2, Spike protein, commensal
57 gut bacteria, vaccine immunogenicity

58

59

60

61

62

63

64

65 Introduction

66 Antibodies are vital components of the immune system that mediate protection
67 against infections (1). When confronting infections, the actual role of
68 pre-existing antibody depends on the following features (2): High titers of
69 broadly neutralizing antibodies can protect the host against infection. While,
70 when the pre-existing antibodies are non-neutralizing or with only a narrow
71 neutralizing spectrum, hosts may not be sterilely protected or only be protected
72 against specific serotypes of viruses. In addition to defending hosts against
73 infections, pre-existing antibodies can also impact host immune responses
74 upon infection or vaccination (3-5), which is best exemplified by the
75 observations showing that pre-existing antibodies shaped the recall immune
76 responses against influenza (6, 7).

77 For most occasions, pre-existing antibodies in adults derive from previous
78 infection or vaccination except some “naturally” produced, poly-reactive
79 antibodies (2, 8). When encountering a newly emerged or mutated virus,
80 cross-reactive antibodies induced by previously occurred, phylogenetically
81 closely related viruses constitute the main body of the pre-existing
82 cross-reactive antibodies. The effect of this kind of pre-existing antibodies has
83 been extensively investigated especially for infections of influenza (3, 7, 9) and
84 flaviviruses (10-12). Of note, previous infection by phylogenetically similar
85 viruses is not the sole source of pre-existing cross-reactive antibodies, as it
86 has been clearly clarified that pre-existing antibodies against HIV-1 gp41 may
87 stem from exposures to certain commensal gut bacteria (13-15). Besides,
88 autoimmune diseases caused by cross-reactivities between microbial and
89 self-antigens also implied that commensal gut bacteria represent important
90 sources of cross-reactive antibodies (16-19).

91 Pre-existing antibodies against SARS-CoV-2 have also been observed in
92 uninfected healthy individuals, which are speculated to be engendered by
93 previous exposures to human common cold coronaviruses (20-26) or
94 SARS-CoV (27-29). Meanwhile, sequence analyses (30) and a clinical
95 observation (31) suggest that pre-existing SARS-CoV-2 antibodies might be
96 engendered by common human pathogens and childhood vaccination.
97 Although these two explanations are not mutually exclusive, they both need
98 more experimental evidence to support.

99 In this study, we found that higher levels of SARS-CoV-2 S2 protein specific

100 antibodies existed in both healthy human and naïve SPF mice. To track the
101 potential origins of these pre-existing cross-reactive antibodies, we mapped
102 and identified a dominant linear antibody epitope on S2, which could be
103 recognized by pre-existing antibodies from both healthy human and naïve SPF
104 mice. Monoclonal antibodies against this linear epitope were isolated from
105 naïve SPF mice and proved to cross-react with commensal gut bacteria
106 collected from both healthy human and naïve SPF mouse. Moreover, despite
107 having been discussed iteratively (32, 33), the influences of pre-existing
108 cross-reactive immunities on COVID-19 responses have not been clarified.
109 Here we showed that high levels of pre-existing antibodies did not impair the
110 immunogenicity of a candidate DNA vaccine encoding SARS-CoV-2 spike
111 protein. On the contrary, mice with high levels of pre-existing antibodies
112 mounted stronger S2 specific binding antibody responses compared with mice
113 with low levels of pre-existing antibodies after immunization with a candidate
114 DNA vaccine. Meanwhile, we showed that inoculation of the SARS-CoV-2 S
115 DNA vaccine could significantly alter the gut microbiota compositions of mice.

116

117 **Results**

118 **Pre-existing antibodies recognizing a dominant linear epitope on** 119 **SARS-CoV-2 S2 protein were detected in both human and mice**

120 Pre-existing antibodies cross-react with SARS-CoV-2 S protein have been
121 found in uninfected individuals by multiple previous studies (22, 25, 26, 34). It
122 was postulated that the pre-existing immunities against SARS-CoV-2 might be
123 induced by previous exposure to seasonal human coronaviruses (22, 32, 33,
124 35, 36). However, contradictory evidence suggested that human common cold
125 coronavirus infection did not necessarily induce antibodies cross-reactive with
126 SARS-CoV-2 spike protein (28, 37, 38). In addition to this hypothesis, an
127 alternative explanation suggested that the cross-reactive immunities to
128 SARS-CoV-2 might derive from other common human pathogens and
129 vaccines (30).

130 To track the origins of the pre-existing cross-reactive antibodies to
131 SARS-CoV-2 spike protein, in this study, we first measured the levels of
132 pre-existing S protein specific antibodies in healthy human individuals and
133 SPF mice. Our data showed that the cross-reactive antibody responses
134 against S2 were significantly stronger than those against S1 in plasma

135 samples of healthy human collected both pre (2016 cohort) and post (2020
136 cohort) the outbreak of COVID-19 pandemic ([Figure 1A and 1B](#)). More
137 strikingly, our data showed that binding antibodies targeting S2 could also be
138 detected in two strains of naïve SPF mice ([Figure 1C and 1D](#)). And this finding
139 was further confirmed by Western-blotting (WB) assays, which showed that
140 mouse sera with high OD values (Detected by ELISA) ([Figure 2A](#)) bound
141 specifically with purified S2 while not S1 ([Figure 2B](#)). Quite interestingly, the
142 WB results indicated that cross-reactive antibodies against S2 also existed in
143 the serum of a mouse (#487) with no detectable ELISA binding signal ([Figure](#)
144 [2A and 2B](#)). We next performed linear antibody epitope mapping using an
145 in-house developed method of peptide competition ELISA. Our data showed
146 that a single peptide (P144, aa1145-aa1162, 18-mer) accounted for most of
147 the observed pre-existing antibody responses towards S2 in mice
148 ([Supplementary Figure 1](#)). Via employing a series of truncated peptides based
149 on P144, we determined the minimal range of this epitope
150 (1147-SFKEELDKYFKNHT-1160), which locates on the connector domain
151 (adjacent to the N-terminal of HR2 domain) ([Figure 2C](#)). We also proved that
152 antibodies recognizing this epitope widely existed in both healthy human and
153 naïve SPF mice through competitive ELISA assays ([Figure 3](#)).

154

155 **The P144 specific antibody responses could be engendered by**
156 **exposures to certain commensal gut bacteria**

157 To explore the potential origins of the pre-existed P144 specific antibodies, we
158 first performed phylogenetic analyses among SARS-CoV-2 and other human
159 coronaviruses. The results showed that the aa sequence of P144 was highly
160 conserved among SARS-CoV-2 variants and SARS-CoV, while the similarities
161 between P144 and MERS-CoV or seasonal human coronaviruses were
162 relatively low, especially within the range of predicted antibody binding epitope
163 (boxed fragment) ([Supplementary Figure 2](#)). The possibility of coronavirus
164 infection in our SPF-mouse colonies was excluded by serum screenings using
165 commercialized mouse hepatitis virus (MHV) antigen (Cat# SBJ-M0051-48T,
166 SinBeiJia Biological Technology Co., Ltd, China) and antibody detection kits
167 (Cat#SY-M02196, Shanghai Shuangying Biotechnology Co., Ltd, China) ([Data](#)
168 [not shown](#)).

169 Subsequently, to investigate whether environmental factors contribute to the

170 induction of these S2 cross-reactive antibodies, we compared the levels of
171 pre-existing S2 binding antibodies between mice housed in SPF condition and
172 mice maintained in a sterile isolation pack. Our data showed that the levels of
173 pre-existing S2 binding antibodies were significantly higher in SPF mice
174 (Figure 4A). Through metagenomic sequencing, we further demonstrated that
175 the compositions of commensal gut bacteria were significantly different
176 between mice housed in different environments (Supplementary Figure 3A).
177 The abundance of bacteroidaceae, prevotellaceae and parabacteroides
178 increased significantly in the commensal gut bacteria of SPF mice (Figure 4B).
179 Moreover, frequencies of memory B cells measured by B cell ELISPOT
180 (Supplementary Figure 3B) and frequencies of S2 specific B cells
181 (CD45+CD19+S2+) measured by flowcytometry (Supplementary Figure 3C)
182 were significantly higher in mesenteric lymph nodes (MLNs) than those in
183 spleens of mice with pre-existing S2 binding antibodies. Consistently, via 16s
184 rDNA sequencing, we found that the gut microbiota compositions of SPF mice
185 with different levels of pre-existing S2 binding antibodies might be different
186 (Supplementary Figure 4). To further clarify the role of gut microbiota in the
187 induction of S2 cross-reactive antibodies, mice fed in a sterile isolation pack
188 were transplanted with fecal bacteria prepared from SPF mice (Figure 4C). We
189 found that the abundances of P144 reactive antibodies in mouse sera
190 significantly increased after fecal microbiota transplantation (FMT) (Figure 4D).
191 These results collectively suggested that the S2 cross-reactive antibodies
192 could be induced by exposures to certain microbial antigens.

193

194 **P144 specific monoclonal antibodies reacted with commensal gut** 195 **bacteria of both human and mouse and showed limited neutralizing** 196 **activities**

197 To probe the potential antigens that might induce the P144 binding antibodies,
198 we isolated 6 mAbs from two naïve SPF mice (one C57BL/6J mouse and one
199 BALB/c mouse) with high levels of pre-existing S2 specific antibody responses.
200 The results of microscale thermophoresis (MST) assays showed that the
201 binding affinities with S2 protein were similar among the 6 mAbs (F5, 2.07 μ M;
202 H9, 0.98 μ M; E10, 3.53 μ M; G13, 2.10 μ M; M3, 1.46 μ M; G18, 2.25 μ M)
203 (Supplementary Figure 5). Five of these mAbs recognized P144 solely
204 (Supplementary Figure 6A), while one mAb (clone M3) bound with P144 and

205 P103 simultaneously ([Supplementary Figure 6B](#)). Results of competitive
206 ELISA showed that the minimal epitopes varied slightly among the five P144
207 specific mAbs, especially at the C-terminal of P144 ([Supplementary Figure 6A](#)).
208 The neutralizing potentials of these isolated monoclonal antibodies were
209 evaluated using a pseudo virus-based neutralization assay. Our results
210 showed that these monoclonal antibodies exhibited limited neutralizing activity
211 against 5 SARS-CoV-2 variants ([Supplementary Figure 7](#)), which might be
212 partially explained by their relatively low affinities to S2 protein ([Supplementary](#)
213 [Figure 5](#)).

214 To prove the cross-reactivities between S2 and commensal gut microbial
215 antigens, whole cell lysates (WCL) of mouse and human commensal gut
216 bacteria were prepared and used as antigens for WB assays, respectively. As
217 shown in [Figure 5A](#), specific bindings with the WCL of mixed fecal bacteria
218 prepared from mice either with low levels of pre-existing antibodies (L) or with
219 high levels of pre-existing antibodies (H) could be clearly visualized for each
220 isolated mAbs. It was noteworthy that all mAbs except E10 strongly recognized
221 a band around 180KD in the sample from mice with high pre-existing antibody
222 responses. E10 predominantly recognized a band around 55KD in both
223 samples, while stronger binding with the sample from mice with high
224 pre-existing antibody responses could be visually observed ([Figure 5A](#)).
225 Among the six mAbs, F5 showed the most diverse binding compacity. In
226 addition to the band around 180KD, F5 bound with a band around 55KD
227 (similar with E10) and a band between 40KD-55KD ([Figure 5A](#)). In comparison
228 with the WB results of mouse samples, the recognized bands were less
229 consistent across different human fecal bacteria samples ([Figure 5B](#)),
230 presumably due to the individual to individual variation of gut microbiota
231 composition. We found that a band around 70KD was recognized by most
232 mAbs in 4 (lanes 1, 5, 6, 7) out of 7 samples and a band between 50KD-70KD
233 was recognized by all mAbs in 3 (Lanes 2, 3, 7) out of 7 samples. Our data
234 showed that the recognition patterns towards each fecal bacteria sample were
235 generally stable across different mAbs except E10 ([Figure 5A and 5B](#)). Then,
236 we performed V(D)J gene sequencing for the 6 antibody clones. Our data
237 showed that the same VH/VL gene combination (IGHV2-5*01, IGKV6-23*01)
238 is used by 4 clones (F5, G18, H9 and M3) ([Supplementary Table 1](#)).
239 Interestingly, among these 4 clones, F5 and M3 were isolated from a C57

240 mouse, while G18 and H9 were isolated from a BALB/c mouse, suggesting it
241 might be a public antibody shared by different mice. G13 uses the same VH
242 gene as the above 4 mAbs in combination with a different VL gene (IGLV2*02).
243 The VH/VL gene usage (IGHV5-9*02, IGKV8-30*01) of E10 is completely
244 different from other clones, which might explain its unique WB patterns shown
245 in [Figure 5A and 5B](#).

246 Proteins corresponding to specifically recognized bands were excised from
247 Coomassie blue stained gels and analyzed by the mass spectrometry. For the
248 mouse fecal bacteria samples, protein bands with molecular weights around
249 180KD, 100KD, 55KD-70KD and 40KD-55KD (indicated by arrows in Figure
250 5A, panel F5) were selected. For human fecal bacteria samples, protein bands
251 with molecular weights around 50KD-70KD, 70KD and 70KD-100KD
252 (indicated by arrows in Figure 5B, panel F5) were selected. The lists of
253 proteins identified in mouse and human samples were shown in [Table 2](#) and
254 [Table 3](#), respectively. Proteins with molecular weights corresponding
255 approximately to the excised protein bands were identified for both human and
256 mouse fecal bacteria samples. Of note, multiple proteins within the theoretical
257 MW range of 58KD to 60KD were found to be identical between mouse and
258 human samples, which included Fumarate hydratase class I (Accession#
259 P14407), Formate-tetrahydrofolate ligase OS (Accession# Q189R2),
260 Phosphoenolpyruvate carboxykinase (ATP) OS (Accession# C4ZBL1 and
261 A6LFQ4) and 60 kDa chaperonin OS (Accession# A0Q2T1). To verify the
262 cross-reactivity of the proteins detected by LC-MS, we selected *E. coli* (DH5 α
263 strain) as a representative target because *E. coli* derived Fumarate hydratase
264 class I (Accession# P14407) were found in both human and mouse fecal
265 bacteria samples. The result of WB assay showed that the P144 specific mAb
266 (Clone F5) recognized multiple bands with MWs consistent with *E. coli* proteins
267 identified by LC-MS ([Figure 5C](#)). Employing an in-house ELISA method, we
268 further proved that one of the isolated mAbs (E10) bound specifically with
269 purified microbial HSP60 and HSP70 proteins ([Figure 5D and 5E](#)), while it did
270 not obviously bind with purified human HSP60 or HSP70 ([Supplementary](#)
271 [Figure 8](#)).

272

273 **Pre-existing S2 cross-reactive antibodies impacted specific immunities**
274 **induced by a candidate COVID-19 DNA vaccine in mice**

275 Pre-existing antibodies has been shown to be able to shape the recall immune
276 responses upon influenza infection and vaccination (6). And the concern about
277 how the pre-existing immunities may influence the effect of a SARS-CoV-2
278 vaccine has also attracted lots of attention (33). To investigate the impact of
279 the pre-existing P144 antibodies on the immunogenicity of a candidate DNA
280 vaccine, 18 BALB/c mice were divided into 3 groups according to their levels of
281 pre-existing S2 binding antibodies and immunized with a DNA vaccine
282 encoding the full length of SARS-CoV-2 S protein (Figure 6A and 6B). Our data
283 showed that mice with high levels of pre-existing S2 binding antibodies
284 mounted significantly higher S2 binding antibody responses after vaccination
285 compared to mice with low or moderate levels of pre-existing S2 binding
286 antibodies (Figure 6C). The average level of P144 specific antibody responses
287 was also stronger in mice with high levels of pre-existing S2 binding antibodies
288 than that of mice with low pre-existing S2 binding antibody responses (Figure
289 6D and 6E). By comparison, both the S1 binding antibody and the neutralizing
290 antibody titers did not significantly differ among all groups, despite that mice
291 with moderate or high levels of pre-existing antibodies tended to mount higher
292 average titer of S1 binding antibodies (Figure 6F and 6G). Mice without
293 vaccination showed neither obvious S1 binding antibody response nor
294 neutralizing activity (Data not shown). We further investigated the influence of
295 pre-existing antibodies on humoral immune responses in mouse respiratory
296 tract after vaccination. And our data showed that the levels of S1 specific IgG
297 in BALF were similar among the three groups after DNA vaccination (Figure
298 7A), while the average level of S2 specific IgG in BALF from mice with high
299 pre-existing S2 binding antibodies was significantly higher than those from
300 mice with low pre-existing antibodies (Figure 7B). S protein specific IgA
301 response did not increase significantly after vaccination as compared with
302 unvaccinated group (Figure 7C and 7D).

303 As the pre-existing antibodies in naïve SPF mice predominantly recognized
304 P144 (Figure 2C and Supplementary Figure 1), we delineated the impact of
305 pre-existing antibodies on the recognition of this epitope after vaccination. Our
306 results showed that the minimum epitope recognition pattern by the sera of
307 mice with high levels of pre-existing antibodies remained unchanged after
308 vaccination (Figure 8). Whereas the minimum epitope recognized by the sera
309 of mice with moderate and low levels of pre-existing antibodies altered at

310 either the N-terminal or both terminals of P144 (Figure 8).

311 In addition to antibody measurement, we compared S protein specific T cell
312 responses among the three groups as well (Figure 9A). The results showed
313 that the candidate DNA vaccine elicited robust S protein specific T cell
314 responses in all groups (Figure 9). Although no statistical significance was
315 reached, interesting trends were observed: First, mice with high levels of
316 pre-existing S2 binding antibodies tended to mount relatively stronger S1 and
317 S2 specific IFN- γ + T cell responses (Figure 9B, 9C and 9D); second, as
318 measured by the releases of IL-6, IL-2 and TNF- α , mice with high levels of
319 pre-existing antibodies tended to mount stronger T cell responses against both
320 S1 and S2 (Figure 9C and 9D). Mice without vaccination showed no S protein
321 specific T cells responses (Data not shown). The major findings of this part of
322 the study were validated by a repeated experiment (Supplementary Figure 9).

323

324 **Pre-existing S2 cross-reactive antibodies correlated with RBD binding** 325 **antibody responses after two-dose inactivated SARS-CoV-2 vaccination**

326 To investigate how the pre-existing cross-reactive antibodies may influence the
327 COVID-19 vaccine induced immunity, peripheral blood samples were collected
328 from 28 healthy individuals who received two doses of an inactivated
329 SARS-CoV-2 vaccine (Figure 10A). Correlation analyses showed that both the
330 OD values (Figure 10B and 10C) and the titers (Supplementary Table 2) of
331 pre-existing S2 reactive antibodies were significantly associated with RBD
332 binding antibody titers at 14 days after immunization. Additionally, although not
333 statistically significant, the pre-existing P144 binding antibody levels tended to
334 correlate positively with neutralizing antibody responses after vaccination
335 (P=0.0946) (Figure 10D).

336

337 **Impact of SARS-CoV-2 S DNA vaccination on the compositions of mouse** 338 **gut microbiota**

339 To explore whether SARS-CoV-2 S DNA vaccination can affect the
340 composition of gut bacteria, mouse stool samples were collected before and
341 after vaccination and analyzed by 16s rDNA sequencing (Supplementary
342 Figure 10A). The results showed that P144 specific antibody increased
343 significantly after DNA vaccination (Supplementary Figure 10B). The PCA
344 analysis showed that the bacterial genera composition of vaccinated mice

345 clearly clustered together ([Supplementary Figure 10C](#)). More specifically, at
346 the genus level, abundances of candidatus saccharimonas and
347 muribaculaceae increased significantly after DNA vaccination, while no
348 significant increase was observed in PBS group ([Supplementary Figure 10D](#)).

349

350 **Discussion**

351 The origins of pre-existing cross-reactive immunities against SARS-CoV-2
352 have been investigated vigorously since the outbreak of the pandemic ([39](#)).
353 Accumulating data suggest that cross-reactive T cells ([33, 40-43](#)) in
354 SARS-CoV-2 unexposed human might be induced by previous infections of
355 other hCoVs. While the origins of pre-existing cross-reactive antibodies could
356 not be completely explained by previous infections of other coronaviruses, as
357 recent studies revealed that the magnitude of antibody responses to
358 SARS-CoV-2 S protein in the sera of patients with COVID-19 was not related
359 to HCoVs' S titers ([44](#)) and immunization with coronaviruses OC43 did not
360 induce significant SARS-CoV-2 S protein cross-reactive antibodies in mice.
361 Moreover, it has also been observed that SARS-CoV-2 S protein specific
362 binding antibody responses were weak in SARS-CoV-2 unexposed individuals
363 with obvious binding antibody responses against S proteins of common cold
364 hCoVs ([45, 46](#)).

365 To track the potential origins of the pre-existed cross-reactive antibodies
366 targeting SARS-CoV-2 spike protein, in this study, we first screened the
367 cross-reactive antibody responses in SARS-CoV-2 unexposed human plasma
368 collected in 2020 and 2016, respectively. In both cohorts, we found that the
369 magnitudes of S2 binding antibodies were significantly higher than those of S1
370 binding antibodies. This finding is consistent with previous studies showing
371 that pre-existing S2 cross-reactive antibody responses are stronger than S1
372 cross-reactive antibody responses in SARS-CoV-2 unexposed individuals ([26,](#)
373 [44, 47, 48](#)). Since S2 cross-reactive antibody responses have also been
374 observed in unexposed animals ([44](#)), we continued to screen the
375 cross-reactive antibody responses in two strains of naïve SPF mice. Our data
376 showed that the OD values of S2 cross-reactive antibodies were significantly
377 higher than those of S1 cross-reactive antibodies in naïve BALB/c and
378 C57BL/6 mice. Detections of mouse sera collected from another two
379 independent SPF animal facilities confirmed this finding ([Data not shown](#)). We

380 also tried to detect the SARS-CoV-2 S protein specific T cells responses in
381 mice with high pre-existing S2 cross-reactive antibodies using the IFN- γ
382 ELISPOT assay, which showed that there was no pre-existing cross-reactive T
383 cell response among these mice ([Data not shown](#)).

384 To facilitate the search of potential antigens that induced the cross-reactive
385 antibodies, we identified a dominant antibody epitope (P144) through a
386 method of competitive ELISA based linear antibody epitope mapping. P144 is
387 located within the connector domain of S2 (aa1147-aa1160, directly N-terminal
388 of the HR2 region). The same epitope has been predicted ([30](#)) and detected in
389 both SARS-CoV-2 unexposed and infected individuals by multiple previous
390 studies ([22](#), [23](#), [25](#), [26](#), [32](#)). In this study, we detected P144 specific antibody
391 responses in plasma samples of healthy individuals collected in both 2020 and
392 2016. More interestingly, we found that the pre-existing S2 cross-reactive
393 antibodies in naïve SPF mice were predominantly against this epitope. Of note,
394 although the aa sequence of P144 is highly conserved among SARS-CoV-2
395 variants and SARS-CoV, its similarity with four seasonal hCoVs is relatively
396 low. It has also been shown that this epitope was more frequently recognized
397 than its homologous peptides from common cold hCoVs by antibodies of
398 COVID-19 negative individuals ([23](#)). These evidence collectively implied that
399 the pre-existing S2 specific antibodies might not be necessarily elicited by
400 previous common cold coronavirus infections.

401 To unveil the origin of the pre-existing S2 binding antibodies in mice, we first
402 measured S2 specific B cells by B cell ELISPOT and flowcytometry and found
403 that the frequency of S2 specific B cells was significantly higher in mesenteric
404 LN than in spleen, suggesting that the gastrointestinal tract might be the
405 primary site where the cross-reactive B cells were activated. As gut bacteria
406 can promote B cell diversification and stimulate antibody production in both
407 T-dependent and -independent ways ([49](#)), we speculated that exposure to
408 certain gut microbial antigens might account for the presence of the
409 cross-reactive antibodies. To prove this hypothesis, we interrogated the
410 relationship between the levels of pre-existing S2 reactive antibodies and the
411 compositions of mouse gut microbiota. Our results showed that mice with
412 different gut microbiota composition had different levels of pre-existing S2
413 cross-reactive antibodies, and vice versa ([Supplementary Figure 4](#)). Moreover,
414 we found that transplantation of fecal bacteria isolated from SPF mice could

415 induce S2 reactive antibodies in mice bred in a sterile isolation pack. The
416 above evidence suggested that the S2 reactive antibodies could be induced by
417 exposure to certain commensal gut bacteria. Nonetheless, the gut microbiota
418 might not be the only factor that can affect the generation of the cross-reactive
419 antibodies, because we observed that mice housed in the same cage could
420 harbor different levels of S2 reactive antibodies ([Data not shown](#)).

421 We are not able to define the bacterial strains contributing to the induction of
422 P144 reactive antibodies in the current study, because it is technically hard to
423 get pure cultures for each potential strain. Instead, we tried to identify potential
424 microbial antigens that may induce the cross-reactive antibodies. To do so, we
425 isolated six P144 specific monoclonal antibodies from a naïve BALB/c mouse
426 and a naïve C57BL/6 mouse, respectively. All the six mAbs were confirmed to
427 be able to bind with P144 and showed weak neutralizing capacities against
428 five SARS-CoV-2 variants. Leveraging these mAbs, we detected the
429 cross-reactive antigens in mouse and human fecal microbiota through WB
430 assays. Compared with a control mouse IgG, specific bands were observed for
431 each mAb, which proved the antibody cross-reactivities between SARS-CoV-2
432 and commensal gut bacteria. The strongly recognized protein bands were
433 further analyzed by LC-MS. Our data showed that cross-reactive antigens
434 derived from bacteroides and parabacteroides were frequently identified in
435 fecal bacteria samples of both human and mouse, which was consistent with
436 our metagenomic sequencing data showing that the abundance of bacteroides
437 and parabacteroides was significantly higher in the commensal gut bacteria of
438 mice with high pre-existing S2 binding antibody levels. More intriguingly, five
439 cross-reactive microbial antigens were identified in mouse and human fecal
440 samples simultaneously, implying that the S2 cross-reactive antibodies might
441 naturally occur in different species of mammals.

442 According to our LC-MS results, few proteins of *E.coli* and HSP60/HSP70
443 proteins of multiple bacterial strains can be recognized by P144 reactive
444 antibodies. These results were verified by experiments showing that P144
445 reactive mAbs could bind with the lysate of an *E.coli* strain (DH5 α) and purified
446 HSP60/HSP70 proteins. However, due to the limited availabilities of pure
447 cultures of commensal gut bacteria and their protein derivatives, we were not
448 able to verify all the potential reactive strains in this study. Alternatively, we
449 tried to refine our LC-MS results through sequence similarity analysis. We

450 found that P144 shared varied identities with LC-MS captured proteins
451 (40%-70%, length \geq 8 aa residues) ([Data not shown](#)). The similarities are not
452 high enough to support confident identifications of potential cross-reactive
453 epitopes based on our current data. To clarify this issue, we plan to expand
454 experimental screening through collaboration in future.

455 In parallel with tracking the initial antigens that induced the S2 cross-reactive
456 antibodies, we investigated the impact of pre-existing antibodies on the
457 immunogenicity of a candidate DNA vaccine as well. According to previous
458 reports, pre-existing cross-reactive antibodies may influence the effects of
459 different vaccines differentially ([6](#), [50](#)). In this study, we found that the
460 pre-existing cross-reactive antibodies shaped the vaccine-induced immune
461 responses in both mouse and human. Mice with high levels of pre-existing
462 antibodies mounted stronger S2 binding antibodies in both peripheral blood
463 and bronchial lavage after vaccination. More interestingly, we found that the
464 pre-existing antibody levels correlated positively with post-vaccination RBD
465 binding antibody titers in human. These findings proved that the pre-existing
466 S2 binding antibodies could facilitate the generation of vaccine induced
467 antibody responses. Through epitope mapping, we observed that the
468 pre-existing antibodies strongly restricted the minimal epitope recognition in
469 mice with high levels of pre-existing antibodies, which suggested that the
470 imprint effect of pre-existing cross-reactive antibodies on vaccine induced
471 antibody responses was primarily epitope specific. In addition to antibody
472 response, we also found that the high levels of pre-existed S2 binding
473 antibodies tended to improve specific T cell responses induced by
474 SARS-CoV-2 S DNA vaccine. Since we did not perform the live virus challenge,
475 it is still not clear how the pre-existing S2 cross-reactive antibodies will impact
476 vaccine efficacy *in vivo*. Nonetheless, as both our results and a recently
477 published study suggested that antibodies targeting P144 epitope could
478 neutralize SARS-CoV-2 ([51](#)), we speculate that the pre-existing P144
479 cross-reactive antibodies may have protective effect. Besides, in this part of
480 the study, we tried but found it may not be appropriate to test the influences of
481 pre-existing antibodies on vaccine elicited immunities through passive
482 antibody transfer, because: First, passive antibody transfer cannot generate
483 S2 reactive memory B cells in recipient mice, which was observed in the
484 mesenteric lymph nodes and spleens of mice with pre-existing S2 reactive

485 antibodies ([Supplementary Figure 3](#)). Second, we found that in vivo antibody
486 level dropped dramatically within 48 hours after tail vein injection and it was
487 technically difficult to maintain relatively stable in vivo antibody level for a long
488 term.

489 A deep understanding of pre-existing cross-reactive antibodies against
490 SARS-CoV-2 will enable better therapeutic, diagnostic and vaccine strategies.
491 In this study, we provided evidence showing that antibodies targeting a
492 conserved linear epitope on S2 cross-reacted with gut microbial antigens from
493 both human and mouse, manifesting that some of the pre-existing
494 cross-reactive antibodies might be induced by exposure to certain commensal
495 gut bacteria. We proved that the pre-existing S2 cross-reactive antibodies did
496 not impair the immunogenicity of a candidate DNA vaccine in a mouse model,
497 while the SARS-CoV-2 S DNA vaccination could significantly change the
498 composition of mouse gut microbiota. Further investigations into the functions
499 of P144 cross-reactive antibodies may assist in delineating the role S2 specific
500 antibody upon SARS-CoV-2 infection and elucidating the mechanisms
501 underlying the gastrointestinal symptom caused by COVID-19 ([52-54](#)).

502

503 **Materials and methods**

504 **Ethics statement**

505 All experiments and methods were performed in accordance with relevant
506 guidelines and regulations. Experiments using mice and samples of healthy
507 human were approved by the Research Ethics Review Committee of the
508 Shanghai Public Health Clinical Center Affiliated to Fudan University.

509

510 **Plasma samples of healthy human**

511 Two batches of plasma samples were collected from healthy individuals at the
512 health screening clinic of Shanghai Public Health Clinical Center. A concurrent
513 batch was collected in December 2020. All the 95 individuals enrolled in this
514 batch reported no epidemiological link with confirmed COVID-19 patients and
515 were confirmed to be free from any chronic or acute disease. Viral RNA tests
516 confirmed that all individuals in this batch were free from SARS-CoV-2
517 infection. In addition, a historical batch of 78 plasma samples from healthy
518 individual cohort (collected in 2016) were also measured for their cross
519 reactivities with SARS-CoV-2 S protein. As the local prevalence in Shanghai

520 was extremely low during previous SARS-CoV-1 epidemic, we did not do the
521 serum screening for previous SARS-CoV-1 infection. Instead, we collected the
522 information regarding previous SARS-CoV-1 infection status through either
523 questionnaire survey (for the 2020 cohort) or telephone follow-up (for the 2016
524 cohort). There is no self-reported previous SARS-CoV-1 infection among the
525 two cohorts. Demographical information about these two cohorts was
526 described in [Table 1](#).

527

528 **Detection of SARS-CoV-2 S1 and S2 specific binding antibodies**

529 In-house enzyme-linked immunosorbent assays (ELISA) were developed to
530 measure SARS-CoV-2 S1 and S2 specific binding antibodies. High-binding
531 96-well EIA plates (Cat# 9018, Corning, USA) were coated with purified
532 SARS-CoV-2 S1 (Cat# 40591-V08H, Sino Biological, China), S2 proteins
533 (Cat# 40590-V08B, Sino Biological, China), recombinant *E.coli* HSP60
534 (Cat#HSP-004, Prospec, Jsrael), *E.coli* HSP70 (Cat#HSP-006, Prospec,
535 Jsrael), human HSP60 (Cat#HSP-016, Prospec, Jsrael) or human HSP70
536 (Cat#HSP-170, Prospec, Jsrael) at a final concentration of 1µg/ml in
537 carbonate/bi-carbonate coating buffer (30mM NaHCO₃,10mM Na₂CO₃, pH
538 9.6). Subsequently, the plates were blocked with 1×PBS containing 5% milk for
539 1 hour at 37°C. Next, 100µl of diluted human plasma, mouse serum or mAbs
540 was added to each well. After 1-hour incubation at 37°C, the plates were
541 washed with 1×PBS containing 0.05% Tween20 for 5 times. Then, 100µl of a
542 HRP labeled rabbit anti-human IgG antibody (Cat# ab6759, Abcam, UK) or
543 goat anti-mouse IgG antibody (Cat# 115-035-003, Jackson Immuno Research,
544 USA) diluted in 1×PBS containing 5% milk were added to each well and
545 incubated for 1 hour at 37°C. After a second round of wash, 100µl of TMB
546 substrate reagent (Cat# MG882, MESGEN, China) was added to each well. 15
547 minutes later, the color development was stopped by adding 100µl of 1M
548 H₂SO₄ to each well and the values of optical density at OD_{450nm} and OD_{630nm}
549 were measured using 800 TS microplate reader (Cat# 800TS, Biotek, USA).

550

551 **Competitive ELISA**

552 According to the reference sequence of SARS-CoV-2 (Genebank accession
553 number: NC_045512), peptides (18-mer overlapping by 11 residues, purities >

554 95%) encompass the full length of S protein were synthesized by GL Biochem
555 (Shanghai, China). The experiment procedure was generally similar with the
556 afore mentioned in-house ELISA assays, except that the diluted mouse serum
557 or human plasma were incubated with synthesized peptides (5µg/ml) or a
558 non-relevant peptide (OVA₃₂₃₋₃₃₉) for 1 hour at room temperature before adding
559 into the coated EIA plates.

560

561 **FACS analysis of S2 specific B cells in mice**

562 Spleen and mesenteric lymph nodes were isolated from naïve SPF mice and
563 single-cell suspensions were freshly prepared. After counting, 1×10^6 single
564 cells were resuspended in 100µl R10 (RPMI1640 containing 10% fetal bovine
565 serum) and incubated with biotinylated S2 protein (Cat# 40590-V08B-B, Sino
566 Biological, China) for 30 minutes at room temperature. After incubation, the
567 cells were washed twice with 500µl R10. Then, the cells were incubated with
568 the mixture of PE-anti-mouse CD19 (Cat# 152408, Biolegend, USA, 1µl/test),
569 BV510-anti-mouse CD45 (Cat# 103137, Biolegend, USA, 1.25µl/test) and
570 Streptavidin-IF647 (Cat# 46006, AAT Bioquest, USA, 0.2µl/test) at room
571 temperature for 30 minutes. After washing, the stained cells were resuspended
572 in 200µl 1×PBS and analyzed using a BD LSRFortessa™ Flow Cytometer.
573 The data were analyzed using the FlowJo software (BD Biosciences, USA).

574

575 **Preparation of P144 specific monoclonal antibodies**

576 Monoclonal antibodies against P144 were prepared from one naïve BALB/c
577 mouse and one naïve C57BL/6 mouse respectively using the hybridoma
578 technique. Briefly, freshly isolated splenocytes were mixed and fused with
579 SP2/0 cells at a ratio of 1:10. Hybridoma cell clones secreting P144 specific
580 antibodies were screened by ELISA and monoclonal hybridoma cells were
581 selected by multiple rounds of limited dilution. Selected clones of hybridoma
582 cells were injected intraperitoneally into BALB/c×ICR hybrid mice. About 1-2
583 weeks later, peritoneal fluid was collected, and monoclonal IgG was purified
584 using Protein A resin. The purities of monoclonal antibodies were verified using
585 SDS-PAGE and the antibody concentrations were determined using a BCA kit
586 (Cat# P0012, Beyotime Biotechnology, China).

587

588 **V(D)J gene sequencing of P144 reactive monoclonal antibodies**

589 The V(D)J genes of P144 reactive monoclonal antibodies were sequenced by
590 AZENTA life science. Briefly, total RNA was extracted from hybridoma cells
591 using Trizol reagent (Cat# R4801-02, Invitrogen, USA). 5` RACE was
592 performed with SMARTer RACE cDNA Amplification Kit (Cat# 634923,
593 Clontech, USA), total RNA input was 500-2000ng. V(D)J genes of heavy and
594 light chains were amplified by PCR. The PCR products were purified through
595 gel extraction using a QIAquick Gel Extraction Kit (Cat# 28704, Qiagen, USA).
596 NGS libraries were constructed by using VAHTS Universal DNA Library Prep
597 Kit for Illumina (Cat# ND607, Vazyme, China). The qualified libraries were
598 sequenced on the Illumina Miseq 2x300 platform (Illumina, San Diego, CA,
599 USA). Raw fastq files were first subject to quality assessment. Adapters and
600 bases with poor quality scores (Q value lower than 20) were removed using
601 Trimmomatic (v0.36) to generate clean data (trimmed data). Pandaseq (2.10)
602 was used to merge pair-end read. Merged sequences were processed by
603 IgBLAST software to identify the V(D)J sequences. The reference sequences
604 were obtained in IMGT database (IMGT, <https://www.imgt.org/>).

605

606 **Isolation of gut commensal bacteria and preparation of whole cell lysate** 607 **(WCL)**

608 About 2g of each fecal sample was suspended with 15ml sterile 1xPBS and
609 vortexed thoroughly to obtain uniform mixtures. After centrifugation at 200xg
610 for 5 min, the supernatants were collected, and the sediments were discarded.
611 This process was repeated twice. Next, all the supernatant samples were
612 centrifuged twice at 9000xg for 5 min and the supernatants were discarded.

613 The precipitated bacteria pellets were resuspended in 500µl of 1xPBS
614 (containing 1mM PMSF) and disrupted with an ultrasonic cell crusher (the
615 probe-type sonicator, Model JY92-II; Ningbo Scientz Biotechnology Co., Ltd,
616 China). After sonication, the samples were centrifuged at 10000rpm for 30
617 minutes to remove the cellular debris.

618

619 **Western blotting**

620 WCL containing 10µg of total protein was separated by SDS-PAGE (10%
621 acrylamide gels) and then transferred onto a PVDF membrane (Cat#

622 IPVH00010, Millipore, USA) or stained with Coomassie brilliant blue. After
623 blocking with 5% skim milk for 2h, the membrane was incubated with a P144
624 specific monoclonal antibody or a control mouse IgG at a concentration of 1
625 µg/ml. After washing, the membrane was incubated with HRP conjugated
626 rabbit anti-human IgG antibody (Cat# ab6759, Abcam, UK) or HRP conjugated
627 goat anti-mouse IgG antibody (Cat # 115-035-003, Jackson Immuno Research,
628 USA) diluted 1:5000 in TBST (Tris-buffered saline, pH 8.0, 0.05% Tween 20)
629 containing 5% skim milk. After wash, the bands were developed with an
630 ultra-sensitive ECL substrate (Cat# K-12045-D10, Advansta, USA). The area
631 corresponding to the specific WB bands were excised from the gel stained with
632 Coomassie blue and analyzed using the mass spectrometry.

633

634 **Mass spectrometry analysis**

635 The FASP digestion was adapted for the following procedures in Microcon
636 PL-10 filters (Cat#MRCPRT010, Merck, USA). After three-time buffer
637 displacement with 8 M Urea (Cat#U111898, Aladdin, China) and 100 mM
638 Tris-HCl, pH 8.5, proteins were reduced by 10 mM DTT (Cat#646563, Sigma
639 Aldrich, USA) at 37 °C for 30 min and followed by alkylation with 30 mM
640 iodoacetamide at 25°C for 45 min in dark. Digestion was carried out with
641 trypsin (enzyme/protein as 1:50) (Cat#T9201, Sigma Aldrich, USA) at 37°C for
642 12 h after a wash with 20% ACN (Cat#34851, Sigma Aldrich, USA) and
643 three-time buffer displacement with digestion buffer (30 mM Tris-HCl, pH 8.0).
644 After digestion, the solution was filtrated out and the filter was washed twice
645 with 15% ACN, and all filtrates were pooled and vacuum-dried to reach a final
646 concentration to 1 mg/ml. LC-MS analysis was performed using a nanoflow
647 EASYnLC 1200 system (Thermo Fisher Scientific, Odense, Denmark) coupled
648 to an Orbitrap Fusion Lumos mass spectrometer (Thermo Fisher Scientific,
649 Bremen, Germany). A one-column system was adopted for all analyses.
650 Samples were analyzed on a home-made C18 analytical column (75 µm i.d. x
651 25 cm, ReproSil-Pur 120 C18-AQ, 1.9 µm (Dr. Maisch GmbH, Germany). The
652 mobile phases consisted of Solution A (0.1% formic acid (Cat#695076, Sigma
653 Aldrich, USA) and Solution B (0.1% formic acid in 80% ACN). The derivatized
654 peptides were eluted using the following gradients: 2–5% B in 2 min, 5–35% B
655 in 100 min, 35–44% B in 6 min, 44–100% B in 3 min, 100% B for 10 min, at a
656 flow rate of 200 nl/min. Data-dependent analysis was employed in MS analysis:

657 The time between master scan was 3s, and fragmented in HCD mode,
658 normalized collision energy was 30.

659

660 **Construction and preparation of a candidate DNA vaccine encoding** 661 **SARS-CoV-2 full length S protein**

662 The full-length s gene sequence of the reference SARS-CoV-2 strain was
663 optimized according to the preference of human codon usage and synthesized
664 by GENEWIZ life science company (Suchow, China). The codon optimized
665 spike gene was subcloned into a eukaryotic expression vector (pJW4303,
666 kindly gifted by Dr. Shan Lu's Laboratory at the University of Massachusetts)
667 (55, 56). And the sequence of inserted gene was verified by Sanger
668 sequencing (Sangon Biotech Co., Ltd., Shanghai, China). An EndoFree
669 Plasmid Purification Kit (Cat#12391, Qiagen, Hilden, USA) was used to
670 prepare the recombinant plasmid for mouse vaccination.

671

672 **Mouse vaccination**

673 Peripheral blood samples were collected from female adult mice and
674 pre-existing S2 binding antibodies were measured using the previously
675 described in-house ELISA method. According to their pre-existing S2 binding
676 antibody levels (at 1:100 dilution of serum), the mice were divided into three
677 groups: low ($0.015 < OD_{450nm-630nm} \leq 0.130$, n=6), moderate ($0.130 <$

678 $OD_{450nm-630nm} \leq 0.750$, n=6) and high ($OD_{450nm-630nm} > 0.750$, n=6). All mice were
679 immunized intramuscularly with the candidate S protein DNA vaccine
680 (50 μ g/mouse) for three times at an interval of 2 weeks. Three weeks post the
681 third vaccination, the mice were euthanized. Peripheral blood, bronchial lavage
682 and spleen were collected for assays of S protein specific immune responses.

683

684 **Metagenomic and 16s rDNA sequencing of mouse gut microbiota**

685 Metagenomic DNA and 16s rDNA were sequenced by SHANGHAI BIOCHIP
686 CO., LTD. For metagenomic DNA sequencing, bacterial DNA was extracted
687 from fecal samples using a TIANamp Stool DNA Kit (Cat#DP328, TIANGEN,
688 China). Then, a total amount of 1 μ g DNA per sample was used as input
689 material for the DNA sample preparations. Metagenomic sequencing libraries
690 were generated using NEBNext® Ultra™ DNA Library Prep Kit for Illumina

691 (Cat#E7103, NEB, USA) following manufacturer's recommendations.
692 Constructed libraries were analyzed for size distribution by Agilent 2100
693 Bioanalyzer and quantified using real-time PCR. The clustering of the
694 index-coded samples was performed on a cBot Cluster Generation System.
695 After cluster generation, the library preparations were sequenced on an
696 Illumina Novaseq 6000 platform and paired-end reads were generated.
697 For 16s rDNA sequencing, fragments of 16s rDNA were amplified with specific
698 barcoded primers 338F (5'-CCTAYGGGRBGCASCAG-3') and 806R
699 (5'-GGACTACNNGGGTATCTAAT-3'). After purification of the PCR product,
700 sequencing libraries were generated using NEBNext® Ultra™ DNA Library
701 Prep Kit for Illumina (Cat#E7654, NEB, USA) following manufacturer's
702 recommendations. After quality evaluation, the library was sequenced on an
703 Illumina Novaseq 6000 platform and 250bp paired-end reads were generated.

704

705 **SARS-CoV-2 pseudo-virus neutralization assay**

706 VSV-backboned SARS-CoV-2 pseudo-viruses were prepared according to a
707 reported method (57). The neutralization assay was conducted by following
708 the previously described procedure (57, 58). Briefly, 100µl of serially diluted
709 mice sera were added into 96-well cell culture plates. Then, 50µl of
710 pseudo-viruses with a titer of 13000 TCID₅₀/ml were added into each well and
711 the plates were incubated at 37°C for 1 hour. Next, Vero cells were added into
712 each well (2×10⁴ cells/well) and the plates were incubated at 37°C in a
713 humidified incubator with 5% CO₂. 24 hours later, luminescence detection
714 reagent (Bright-Glo™ Luciferase Assay System, Promega, USA) was added to
715 each well following the manufacturer's instruction. The luminescence was
716 measured using a luminescence microplate reader (GloMax®
717 Navigator Microplate Luminometer, Promega, USA) within 5 minutes. The
718 Reed-Muench method was used to calculate the virus neutralization titer.
719 Antibody neutralization titers were presented as 50% maximal inhibitory
720 concentration (IC₅₀).

721

722 **Detections of S protein specific cellular immune responses**

723 SARS-CoV-2 S protein specific IFN-γ releases were measured using the
724 method of enzyme-linked immunosorbent spot (ELISPOT) assays (Cat#
725 551083, BD Bioscience, USA) according to a previously described procedure

726 (59). Briefly, the 96-well ELISPOT plates were coated with purified anti-mouse
727 IFN- γ monoclonal antibody overnight at 4°C. Then, the plates were blocked
728 and 2×10^5 fresh splenocytes were added into each well and incubated with
729 peptide pools for 20 hours at 37°C in a humidified incubator with 5% CO₂. The
730 final concentration for each peptide was 1 μ g/ml. After incubation, detecting
731 antibody and Avidin-HRP were added sequentially. Finally, the plates were
732 developed using the BD™ ELISPOT AEC Substrate Set (Cat#551951, BD
733 Bioscience, USA) according to the manufacturer's manual. Spots representing
734 IFN- γ producing cells were enumerated using an automated ELISPOT plate
735 reader (ChampSpot III Elispot Reader, Saizhi, Beijing, China). At the same
736 time, the supernatants in the wells of ELISPOT plates were also collected for
737 detecting secreted cytokines using a multiplexed cytokine beads array kit
738 (Cat#741054, Biolegend, USA).

739

740 **Statistical analysis**

741 All statistical analyses were performed using GraphPad Prism 8
742 (GraphPad Software, Inc., La Jolla, CA, USA). Comparisons between two
743 groups were conducted by the method of *t*-test. Comparisons among three or
744 more group were done using one-way ANOVA. *P*<0.05 was considered as
745 statistically significant.

746

747 **Acknowledgements**

748 We thank Miss Zhangyufan He from Huashan Hospital, Fudan University, for
749 her kind help with the language polishing. This work was funded by the
750 National Natural Science Foundation of China (Grant No. 81971559,
751 82041010, 81971900, 31872744), National Science and Technology Major
752 Project (Grant No. 2018ZX10731301-004, 2018ZX10302302-002 and
753 2018ZX10301-404-002-003) and the Science and Technology Commission of
754 Shanghai Municipality (Grant No. 20411950400).

755

756 **Author contributions**

757 Y.M.W., Y.X., C.Q., Z.Q.Z. and W.H.Z. designed the study. L.Q.J., S.F.W.,
758 Y.M.W., X.X.T., Y.F.Z., J.W., X.Y.W., and J.W. conducted the experiments.

759 Y.M.W., L.Q.J. and S.F.W. analyzed the data and drafted the manuscript.
760 Y.M.W., Y.X., C.Q., Z.Q.Z., W.H.Z. and F.F. revised the manuscript. D.M.Y.
761 and W.H.W. provided intellectual inputs in tackling technical challenges in
762 tracking the potential cross-reacting antigens.

763

764 **Conflict of Interest**

765 The authors declare that they have no relevant conflicts of interest.

766

767 **Data availability**

768 The data of metagenomic analysis of gut microbiota has been deposited to the
769 NCBI Sequence Read Archive (SRA) database with the accession number
770 PRJNA747837.

771

772 **References**

- 773 1. Lu LL, Suscovich TJ, Fortune SM, Alter G. Beyond binding: antibody effector functions in
774 infectious diseases. *Nature reviews Immunology*. 2018;18(1):46-61.
- 775 2. Warter L, Appanna R, Fink K. Human poly- and cross-reactive anti-viral antibodies and their
776 impact on protection and pathology. *Immunologic research*. 2012;53(1-3):148-61.
- 777 3. Cobey S, Hensley SE. Immune history and influenza virus susceptibility. *Current opinion in*
778 *virology*. 2017;22:105-11.
- 779 4. Mok DZL, Chan KR. The Effects of Pre-Existing Antibodies on Live-Attenuated Viral Vaccines.
780 *Viruses*. 2020;12(5).
- 781 5. Zimmermann P, Curtis N. Factors That Influence the Immune Response to Vaccination. *Clinical*
782 *microbiology reviews*. 2019;32(2).
- 783 6. Dugan HL, Guthmiller JJ, Arevalo P, Huang M, Chen YQ, Neu KE, et al. Preexisting immunity
784 shapes distinct antibody landscapes after influenza virus infection and vaccination in humans. *Science*
785 *translational medicine*. 2020;12(573).
- 786 7. Zhang A, Stacey HD, Mullarkey CE, Miller MS. Original Antigenic Sin: How First Exposure
787 Shapes Lifelong Anti-Influenza Virus Immune Responses. *Journal of immunology (Baltimore, Md :*
788 *1950)*. 2019;202(2):335-40.
- 789 8. Boes M. Role of natural and immune IgM antibodies in immune responses. *Molecular*
790 *immunology*. 2000;37(18):1141-9.
- 791 9. Auladell M, Jia X, Hensen L, Chua B, Fox A, Nguyen THO, et al. Recalling the Future:
792 Immunological Memory Toward Unpredictable Influenza Viruses. *Frontiers in immunology*.
793 2019;10:1400.
- 794 10. St. John AL, Rathore APS. Adaptive immune responses to primary and secondary dengue virus
795 infections. *Nature Reviews Immunology*. 2019;19(4):218-30.
- 796 11. Izmirly AM, Alturki SO, Alturki SO, Connors J, Haddad EK. Challenges in Dengue Vaccines
797 Development: Pre-existing Infections and Cross-Reactivity. 2020;11(1055).
- 798 12. Andrade P, Gimblet-Ochieng C, Modirian F, Collins M, Cárdenas M, Katzelnick LC, et al. Impact

- 799 of pre-existing dengue immunity on human antibody and memory B cell responses to Zika. *Nature*
800 *Communications*. 2019;10(1):938.
- 801 13. Liao HX, Chen X, Munshaw S, Zhang R, Marshall DJ, Vandergrift N, et al. Initial antibodies
802 binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. *The Journal of*
803 *experimental medicine*. 2011;208(11):2237-49.
- 804 14. Bonsignori M, Liao HX, Gao F, Williams WB, Alam SM, Montefiori DC, et al. Antibody-virus
805 co-evolution in HIV infection: paths for HIV vaccine development. *Immunological reviews*.
806 2017;275(1):145-60.
- 807 15. Williams WB, Liao HX, Moody MA, Kepler TB, Alam SM, Gao F, et al. HIV-1 VACCINES.
808 Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. *Science*
809 (New York, NY). 2015;349(6249):aab1253.
- 810 16. Zitvogel L, Ayyoub M, Routy B, Kroemer G. Microbiome and Anticancer Immunosurveillance.
811 *Cell*. 2016;165(2):276-87.
- 812 17. Leng Q, Tarbe M, Long Q, Wang F. Pre-existing heterologous T-cell immunity and neoantigen
813 immunogenicity. *Clinical & translational immunology*. 2020;9(3):e01111.
- 814 18. Sioud M. T-cell cross-reactivity may explain the large variation in how cancer patients respond to
815 checkpoint inhibitors. *Scandinavian journal of immunology*. 2018;87(3).
- 816 19. Rose NR. Negative selection, epitope mimicry and autoimmunity. *Current opinion in immunology*.
817 2017;49:51-5.
- 818 20. Anderson EM, Goodwin EC, Verma A, Arevalo CP, Bolton MJ, Weirick ME, et al. Seasonal
819 human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with
820 protection. *Cell*. 2021.
- 821 21. Galipeau Y, Greig M, Liu G, Driedger M, Langlois MA. Humoral Responses and Serological
822 Assays in SARS-CoV-2 Infections. *Frontiers in immunology*. 2020;11:610688.
- 823 22. Klompus S, Leviatan S, Vogl T, Kalka IN, Godneva A, Shinar E, et al. Cross-reactive antibody
824 responses against SARS-CoV-2 and seasonal common cold coronaviruses. 2020:2020.09.01.20182220.
- 825 23. Shrock E, Fujimura E, Kula T, Timms RT, Lee IH, Leng Y, et al. Viral epitope profiling of
826 COVID-19 patients reveals cross-reactivity and correlates of severity. *Science (New York, NY)*.
827 2020;370(6520).
- 828 24. Ortega N, Ribes M, Vidal M, Rubio R, Aguilar R, Williams S, et al. Seven-month kinetics of
829 SARS-CoV-2 antibodies and protective role of pre-existing antibodies to seasonal human coronaviruses
830 on COVID-19. 2021:2021.02.22.21252150.
- 831 25. Ladner JT, Henson SN, Boyle AS, Engelbrektsen AL, Fink ZW, Rahee F, et al. Epitope-resolved
832 profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human
833 coronaviruses. *Cell reports Medicine*. 2021;2(1):100189.
- 834 26. Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, et al. Preexisting and de novo
835 humoral immunity to SARS-CoV-2 in humans. *Science (New York, NY)*. 2020;370(6522):1339-43.
- 836 27. Yang R, Lan J, Huang B, A R, Lu M, Wang W, et al. Lack of antibody-mediated cross-protection
837 between SARS-CoV-2 and SARS-CoV infections. *EBioMedicine*. 2020;58:102890.
- 838 28. Lv H, Wu NC, Tsang OT, Yuan M, Perera R, Leung WS, et al. Cross-reactive Antibody Response
839 between SARS-CoV-2 and SARS-CoV Infections. *Cell reports*. 2020;31(9):107725.
- 840 29. Zhu Y, Yu D, Han Y, Yan H, Chong H, Ren L, et al. Cross-reactive neutralization of SARS-CoV-2
841 by serum antibodies from recovered SARS patients and immunized animals. *Science advances*.
842 2020;6(45).


- 843 30. Reche PA. Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens
844 and Vaccines. *Frontiers in immunology*. 2020;11:586984.
- 845 31. Sumbul B, Sumbul HE, Okyay RA, Gülümsek E, Şahin AR, Boral B, et al. Is there a link between
846 pre-existing antibodies acquired due to childhood vaccinations or past infections and COVID-19? A
847 case control study. *PeerJ*. 2021;9:e10910.
- 848 32. Majdoubi A, Michalski C, O'Connell SE, Dada S, Narpala SR, Gelinas JP, et al. A majority of
849 uninfected adults show pre-existing antibody reactivity against SARS-CoV-2. *JCI insight*. 2021.
- 850 33. Sette A, Crotty S. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. *Nature*
851 *reviews Immunology*. 2020;20(8):457-8.
- 852 34. Tso FY, Lidenge SJ, Peña PB, Clegg AA, Ngowi JR, Mwaiselage J, et al. High prevalence of
853 pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2
854 (SARS-CoV-2) in sub-Saharan Africa. *International journal of infectious diseases : IJID : official*
855 *publication of the International Society for Infectious Diseases*. 2021;102:577-83.
- 856 35. Lipsitch M, Grad YH, Sette A, Crotty S. Cross-reactive memory T cells and herd immunity to
857 SARS-CoV-2. *Nature reviews Immunology*. 2020;20(11):709-13.
- 858 36. Lee CH, Pinho MP, Buckley PR, Woodhouse IB, Ogg G, Simmons A, et al. Potential CD8+ T Cell
859 Cross-Reactivity Against SARS-CoV-2 Conferred by Other Coronavirus Strains. *Frontiers in*
860 *immunology*. 2020;11:579480.
- 861 37. Freeman B, Lester S, Mills L, Rasheed MAU, Moye S, Abiona O, et al. Validation of a
862 SARS-CoV-2 spike protein ELISA for use in contact investigations and sero-surveillance.
863 2020:2020.04.24.057323.
- 864 38. Post N, Eddy D, Huntley C, van Schalkwyk MCI, Shrotri M, Leeman D, et al. Antibody response
865 to SARS-CoV-2 infection in humans: A systematic review. *PloS one*. 2020;15(12):e0244126.
- 866 39. Doshi P. Covid-19: Do many people have pre-existing immunity? 2020;370:m3563.
- 867 40. Steiner S, Sotzny F, Bauer S, Na I-K, Schmueck-Henneresse M, Corman VM, et al. HCoV- and
868 SARS-CoV-2 Cross-Reactive T Cells in COVID Patients. 2020;11(3347).
- 869 41. Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, et al. Selective and cross-reactive
870 SARS-CoV-2 T cell epitopes in unexposed humans. 2020;370(6512):89-94.
- 871 42. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell
872 Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed
873 Individuals. *Cell*. 2020;181(7):1489-501.e15.
- 874 43. Braun J, Loyal L, Frensch M, Wendisch D, Georg P, Kurth F, et al. SARS-CoV-2-reactive T cells
875 in healthy donors and patients with COVID-19. *Nature*. 2020;587(7833):270-4.
- 876 44. Kim H, Seiler P, Jones JC, Ridout G, Camp KP, Fabrizio TP, et al. Antibody Responses to
877 SARS-CoV-2 Antigens in Humans and Animals. *Vaccines*. 2020;8(4).
- 878 45. Anderson EM, Goodwin EC, Verma A, Arevalo CP, Bolton MJ, Weirick ME, et al. Seasonal
879 human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with
880 protection. *Cell*. 2021;184(7):1858-64.e10.
- 881 46. Song G, He W-t, Callaghan S, Anzanello F, Huang D, Ricketts J, et al. Cross-reactive serum and
882 memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. *Nature*
883 *Communications*. 2021;12(1):2938.
- 884 47. Fraley E, LeMaster C, Banerjee D, Khanal S, Selvarangan R, Bradley T. Cross-reactive antibody
885 immunity against SARS-CoV-2 in children and adults. *Cellular & molecular immunology*. 2021:1-3.
- 886 48. Nguyen-Contant P, Embong AK, Kanagaiah P, Chaves FA, Yang H, Branche AR, et al. S

- 887 Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes
888 Broad Reactivity to the S2 Subunit. *mBio*. 2020;11(5).
- 889 49. Zhao Q, Elson CO. Adaptive immune education by gut microbiota antigens. *Immunology*.
890 2018;154(1):28-37.
- 891 50. Bradt V, Malafa S, von Braun A, Jarmer J, Tsouchnikas G, Medits I, et al. Pre-existing yellow
892 fever immunity impairs and modulates the antibody response to tick-borne encephalitis vaccination.
893 *NPJ vaccines*. 2019;4:38.
- 894 51. Pinto D, Sauer MM, Czudnochowski N, Low JS, Tortorici MA, Housley MP, et al. Broad
895 betacoronavirus neutralization by a stem helix-specific human antibody. *Science (New York, NY)*.
896 2021.
- 897 52. Lee IC, Huo TI, Huang YH. Gastrointestinal and liver manifestations in patients with COVID-19.
898 *Journal of the Chinese Medical Association : JCMA*. 2020;83(6):521-3.
- 899 53. Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, et al. Epidemiological, clinical and virological
900 characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal
901 symptoms. *Gut*. 2020;69(6):1002-9.
- 902 54. Mao R, Qiu Y, He JS, Tan JY, Li XH, Liang J, et al. Manifestations and prognosis of
903 gastrointestinal and liver involvement in patients with COVID-19: a systematic review and
904 meta-analysis. *The lancet Gastroenterology & hepatology*. 2020;5(7):667-78.
- 905 55. Lu S, Manning S, Arthos J. Antigen engineering in DNA immunization. *Methods in molecular
906 medicine*. 2000;29:355-74.
- 907 56. Fan W, Wan Y, Li Q. Interleukin-21 enhances the antibody avidity elicited by DNA prime and
908 MVA boost vaccine. *Cytokine*. 2020;125:154814.
- 909 57. Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, et al. Establishment and validation of a pseudovirus
910 neutralization assay for SARS-CoV-2. *Emerging microbes & infections*. 2020;9(1):680-6.
- 911 58. Li Q, Wu J, Nie J, Zhang L, Hao H, Liu S, et al. The Impact of Mutations in SARS-CoV-2 Spike
912 on Viral Infectivity and Antigenicity. *Cell*. 2020;182(5):1284-94.e9.
- 913 59. Ren Y, Wang N, Hu W, Zhang X, Xu J, Wan Y. Successive site translocating inoculation
914 potentiates DNA/recombinant vaccinia vaccination. *Scientific reports*. 2015;5:18099.


Figures and Figure legends

Figure 1


A



B



C



D




Figure 1 Pre-existing cross-reactive antibodies against SARS-CoV-2 S protein observed in both healthy human and naïve SPF mice predominantly targeted S2. The pre-existing cross-reactive antibodies against S1 and S2 were measured using an in-house ELISA method (Sample dilution factor: 100). (A) Plasma samples of healthy individuals collected in 2020 (n=95). (B) Plasma samples of healthy individuals collected in 2016 (n=78). (C) Sera of naïve C57BL/6J mice (n=12). (D) Sera of naïve BALB/c mice (n=101). The dotted lines show the threshold of background (3 folds of the average background OD). Statistical analyses were performed using the method of paired t-test.

Figure 2




Figure 2 The pre-existing S protein binding antibodies in naïve SPF mice recognized S2 exclusively and a dominant linear antibody epitope was identified on the connector domain. (A) The pre-existing S1 and S2 reactive antibody levels in the sera of 6 representative mice. (B) WB assays of pre-existing cross-reactive antibodies for 6 representative mouse serum samples. The purities of S1 and S2 proteins were shown by coomassie blue staining. (C) The minimal epitope of P144 was defined using a method of competitive ELISA (Data shown as mean±SD, n=5). Purified S2 protein was used as the coating antigen and truncated peptides derived from P144 were used as competitors. The decreases of competitive inhibition reflected the necessity of each amino acid for the epitope recognition. Statistical differences among groups was analyzed using One-way ANOVA. ****, P<0.0001. M: molecular weight marker; SP, signal peptide; RBD, receptor-binding domain; FP, fusion peptide; HR, heptad repeat; CH, central helix; CD, connector domain; TM, transmembrane domain; CT, cytoplasmic tail.

Figure 3




Figure 3 P144 reactive antibodies widely existed in both healthy human and naïve SPF mice. P144 specific binding antibodies were detected using a method of competitive ELISA. (A) For the detections of P144 specific binding antibodies in naïve SPF mice, purified S2 protein was used as the coating antigen and P144 peptide was used as the competitor. (B) For the detections of P144 specific binding antibodies in healthy individuals, purified BSA-P144 conjugate was used as the coating antigen and P144 peptide was used as the competitor. In both experiments, the reduction of OD value reflected the presence of P144 binding antibodies.

Figure 4




Figure 4 The presence of the pre-existing S2 reactive antibodies was associated with commensal gut bacteria. **(A)** Comparison of the levels of S2 reactive antibodies between naïve mice maintained under SPF condition and mice housed in a sterile isolation pack. **(B)** Metagenomic analyses of gut microbiota compositions between mice from different housing environments. Differences of bacterial abundance were manifested by linear discriminant analysis (LDA) . **(C)** Schematic overview of the fecal bacteria transplantation (n=6). The mice bred in a sterile isolation pack were treated with a mixture of ampicillin (1g/L), metronidazole (0.5g/L), vancomycin (0.5g/L) and gentamycin (0.5g/L) dissolved in drinking water supplemented with D-glucose (36.8g/L) for 14 days. Two weeks later, fecal bacteria were freshly prepared from SPF mice and delivered to antibiotic treated mice via oral gavage. **(D)** Comparison of P144 reactive antibodies in mouse sera collected before and after FMT. The OD value of P144 binding antibody was normalized to the concentration of total IgG for each mouse. Data are shown as mean±SD (n=6). Statistical analyses were performed by the method of paired t-test. (p), Phylum. (c), Class. (o), Order. (f), Family. (g), Genus. (s), Species.




Figure 5 P144 binding mAbs isolated from naïve SPF mice reacted with commensal gut bacteria from both human and mouse. Reactivities between P144 binding mAbs and gut microbial antigens were detected using WB assays. A purified mouse IgG was used as the control. **(A)** WB assays of mouse fecal bacteria samples. L: mixed fecal bacteria samples collected from 3 mice with low levels of pre-existing S2 binding antibodies ($OD_{450nm-630nm} \leq 0.140$, 1:100 diluted); H: mixed fecal bacteria samples collected from 3 mice with high levels of pre-existing S2 binding antibodies ($OD_{450nm-630nm} \geq 0.615$, 1:100 diluted). **(B)** WB assays of fecal bacteria samples collected from 7 healthy individuals (Lanes 1-7). All the mAbs and the control mouse IgG were tested at the final concentration of 1 μ g/ml. Black arrows indicate the locations of protein bands selected for the mass spectrometry analysis. **(C)** Reactivity between a P144 specific mAb (clone F5) and *E. coli* was validated by WB. F5 or a purified mouse IgG was used as the first antibody at the concentration of 1 μ g/ml. Black arrows point out the bands with MWs equal to *E. coli* proteins identified by LC-MS analysis. **(D)** Recognition of purified *E. coli* HSP60 protein by P144 reactive antibodies. **(E)** Recognition of purified *E. coli* recombinant HSP70 protein by P144 reactive antibodies. All the mAbs and control IgG were measured at a final concentration of 10 μ g/ml. Dotted line represents the mean OD value of control IgG plus 2-fold SD (mean+2SD).

Figure 6




Figure 6 Impacts of pre-existing antibodies on the humoral immune responses elicited by a DNA vaccine encoding SARS-CoV-2 S protein. (A) Schematic illustration of the experiment schedule. 50 μ g of the DNA vaccine was injected intra muscularly into each mice at week 0, week 2 and week 4, respectively. Two weeks after the final vaccination, the mice was euthanized for the measurements of specific immune responses. (B) Peripheral blood was collected before immunization and levels of pre-existing S2 specific antibodies were compared among groups. (C) Endpoint IgG titers against S2 were compared at 2 weeks post the last immunization. (D) Comparisons of P144 specific IgG titers as measured using BSA-P144 conjugate as the coating antigen. (E) Comparisons of P144 specific binding antibody levels as determined using a method of competitive ELISA. (F) Endpoint IgG titers against S1 measured at 2 weeks post the final vaccination. (G) Neutralizing antibody titers against SARS-CoV-2 D614G pseudo-virus in serum of mice at 2 weeks post the final immunization. Data were shown as mean \pm SD, n=6. Statistical analyses were performed by the method of one-way ANOVA.

Figure 7




Figure 7 The impacts of pre-existing antibody on the levels of specific IgG and IgA in BALF after vaccination. BALF was collected from each mouse after euthanasia. Specific IgG (A and B) and IgA (C and D) against S1 or S2 were detected using in-house ELISA methods. All the BALF samples were adjusted to the initial total protein concentration of 51.9 μ g/ml. Data are shown as mean \pm SD, n=6. Statistical analyses were performed by the method of one-way ANOVA.

Figure 8




Figure 8 The impact of pre-existing antibody on the recognition of the minimum epitope of P144 after vaccination. The minimal epitope recognized by mouse sera after vaccination was analyzed using a method of competitive ELISA. Purified BSA-P144 conjugate was used as the coating antigen and truncated peptides derived from P144 were used as the competitors. The decreases of competitive inhibition reflected the necessity of each amino acid for the epitope recognition. Statistical analyses were performed by the method of two-tailed t-test (*, $P < 0.05$, **, $P < 0.01$, ***, $P < 0.001$).

Figure 9






Figure 9 The impacts of pre-existing antibody on the cellular immune responses after vaccination. (A) The diagram of the method used for cellular immune responses evaluation. (B) S1 and S2 specific IFN- γ responses were compared among groups of mice with different levels of pre-existing S2 reactive antibodies. Additionally, S1 (C) and S2 (D) specific releases of IL-2, IL-6 and TNF- α as measured using the method of multiplex cytokine bead assay were also compared among different groups. Data were shown as mean \pm SD, n=6. SFCs, spot forming cells.

Figure 10


A



B



C



D




Figure 10 Levels of pre-existing S2 reactive antibodies correlated with RBD binding antibody responses elicited by an inactivated SARS-CoV-2 vaccine in human. (A) Peripheral blood samples were collected from 28 healthy vaccines who received two doses of an inactivated SARS-CoV-2 vaccine at baseline and 14 days post the 2nd dose, respectively. The RBD binding antibody titers were measured by ELISA. The neutralizing antibody responses were quantified by a commercialized surrogate virus neutralization test (sVNT) (Suzhou Sym-Bio Life Science Co., Ltd). **(B and C)** Correlations between RBD binding antibody titers and levels of pre-existing S2 or P144 specific IgG. **(D)** Correlation between neutralizing antibody concentrations and pre-existing P144 binding antibody levels. Statistical analyses were performed using the method of Spearman's correlation. The experiment was repeated twice.

Table 1 Demographics of SARS-CoV-2 unexposed healthy individuals

Sample Collection Time	2016	2020
Number of individuals	78	95
Gender (males, females)	17, 61	78, 17
Age, years (mean \pm SD)	35.88 \pm 8.40	30.40 \pm 7.55

Table 2 Potential cross-reactive antigens identified in mouse fecal bacteria

NCBI Accession #	Protein name	Bacterium	Score	Proteins	Unique Peptides	Peptides	PSMs	Area	MW [kDa]
Q8A470	DNA-directed RNA polymerase subunit beta' OS	Bacteroides thetaiotaomicron	168.01	550	2	6	6	3.536E7	158.3
Q5L897	DNA-directed RNA polymerase subunit beta OS	Bacteroides fragilis	92.15	8	2	3	3	8.315E6	142.4
Q8A1G1	TonB-dependent receptor SusC OS	Bacteroides thetaiotaomicron	145.74	1	1	2	3	1.385E8	111.1
Q46509	Aldehyde oxidoreductase OS	Desulfovibrio gigas	75.93	1	1	1	1	8.506E6	97.0
P22983	Pyruvate, phosphate dikinase OS	Clostridium symbiosum	109.83	7	2	2	2	3.721E7	96.6
P0A9Q8	Aldehyde-alcohol dehydrogenase OS	Escherichia coli	34.29	1	1	1	1	1.085E7	96.1
Q826F6	Chaperone protein dnaK2 OS	Streptomyces avermitilis	20.37	1	1	1	1	1.059E7	67.5
Q892R0	Chaperone protein DnaK OS	Clostridium tetani	51.52	5	1	1	1	1.780E7	66.4
B119W8	L-fucose isomerase OS	Streptococcus pneumoniae	57.33	12	2	2	2	2.792E7	65.7
P95334	Chaperone protein DnaK OS	Myxococcus xanthus	39.23	4	1	1	1	1.792E7	65.3
Q1MPZ9	Formate--tetrahydrofolate ligase OS	Lawsonia intracellularis	62.49	1	2	2	2	2.068E7	64.2
P26929	Urease subunit alpha OS	Lactobacillus fermentum	134.06	4	4	4	5	1.526E7	61.8
Q9I165	Periplasmic trehalase OS	Pseudomonas aeruginosa	77.05	1	1	1	1	4.240E8	61.1
Q9EZ02	Pyrophosphate--fructose 6-phosphate 1-phosphotransferase OS	Spirochaeta thermophila	68.21	2	1	1	1	1.192E7	61.0
P14407	Fumarate hydratase class I, anaerobic OS	Escherichia coli	30.79	1	1	1	1	6.580E6	60.1
Q189R2	Formate--tetrahydrofolate ligase OS	Clostridioides difficile	123.52	22	3	4	4	2.621E7	59.9
P22252	Flagellin B OS	Campylobacter jejuni subsp. jejuni serotype O:6	75.42	1	1	1	1	1.478E7	59.7
Q1WTV0	Formate--tetrahydrofolate ligase OS	Lactobacillus salivarius	83.43	23	1	1	1	5.229E7	59.4
A7HLZ4	Formate--tetrahydrofolate ligase OS	Fervidobacterium nodosum	93.49	29	1	2	2	8.036E6	59.2
C4ZBL1	Phosphoenolpyruvate carboxykinase (ATP) OS	Agathobacter rectalis	211.34	4	1	4	5	3.965E7	59.0
A6LFQ4	Phosphoenolpyruvate carboxykinase (ATP) OS	Parabacteroides distasonis	32.29	1	1	1	1	8.523E6	58.9
A3MZI4	Formate--tetrahydrofolate ligase OS	Actinobacillus pleuropneumoniae serotype 5b	78.45	78	1	2	2	1.320E8	58.9
Q2LPJ8	60 kDa chaperonin 1 OS	Syntrophus aciditrophicus	101.22	15	1	2	3	2.217E7	58.6
Q3ALZ3	60 kDa chaperonin 1 OS	Synechococcus sp.	113.34	23	1	2	3	9.973E7	58.5
B8J123	60 kDa chaperonin OS	Desulfovibrio desulfuricans	232.59	27	2	5	6	9.659E7	58.4
Q72AL6	60 kDa chaperonin OS	Desulfovibrio vulgaris	126.02	9	1	3	3	2.402E7	58.4

A0Q2T1	60 kDa chaperonin OS	<i>Clostridium novyi</i>	78.78	16	1	2	2	2.292E7	58.1
B0SCC0	60 kDa chaperonin OS	<i>Leptospira biflexa</i> serovar Patoc	49.58	1	1	1	1	1.882E8	58.1
B2TIX0	60 kDa chaperonin OS	<i>Clostridium botulinum</i>	126.34	35	1	3	3	4.903E7	57.9
A7GZ43	60 kDa chaperonin OS	<i>Campylobacter curvus</i>	105.05	41	2	3	3	5.327E7	57.9
Q67KB8	60 kDa chaperonin OS	<i>Symbiobacterium thermophilum</i>	107.47	126	1	3	3	9.411E7	57.9
B5YDR9	60 kDa chaperonin OS	<i>Dictyoglomus thermophilum</i>	59.61	2	1	1	1	3.345E7	57.9
Q3ADX3	60 kDa chaperonin OS	<i>Carboxydotherrmus hydrogenoformans</i>	104.07	25	1	2	3	7.715E7	57.6
O50305	60 kDa chaperonin OS	<i>Bacillus halodurans</i>	250.57	55	3	4	6	3.021E8	57.4
P26821	60 kDa chaperonin OS	<i>Clostridium perfringens</i>	131.27	36	1	3	3	4.609E7	57.3
P37282	60 kDa chaperonin OS	<i>Lactococcus lactis</i> subsp. <i>lactis</i>	102.15	18	1	2	2	4.298E7	57.2
C4ZD46	60 kDa chaperonin OS	<i>Agathobacter rectalis</i>	372.10	52	3	5	8	3.352E8	57.1
A6L8C4	Glucose-6-phosphate isomerase OS	<i>Parabacteroides distasonis</i>	88.85	55	1	2	3	5.392E8	48.7
P43793	NADP-specific glutamate dehydrogenase OS	<i>Haemophilus influenzae</i>	96.32	2	1	2	2	7.357E7	48.6
P00370	NADP-specific glutamate dehydrogenase OS	<i>Escherichia coli</i>	161.88	1	1	3	4	3.280E8	48.6
P15111	NADP-specific glutamate dehydrogenase OS	<i>Salmonella typhimurium</i>	185.28	4	1	4	5	1.755E8	48.5
P94316	NAD-specific glutamate dehydrogenase OS	<i>Bacteroides fragilis</i>	192.93	3	3	5	6	1.730E8	48.4
Q1WSY0	Enolase OS	<i>Lactobacillus salivarius</i>	79.89	8	3	3	3	1.340E7	48.0
B7MD95	Trigger factor OS	<i>Escherichia coli</i> O45:K1	78.80	10	2	2	2	4.344E7	47.8
B2GAM0	Enolase OS	<i>Lactobacillus fermentum</i>	79.94	8	2	2	2	1.858E7	47.8
Q6MEY2	Enolase OS	<i>Protochlamydia amoebophila</i>	112.67	1	1	1	1	7.493E7	47.5
Q0SNH5	Enolase OS	<i>Borrelia afzelii</i>	71.86	2	1	1	1	4.654E7	47.4
G3KIM4	Lactoyl-CoA dehydratase subunit alpha (Fragment) OS	<i>Anaerotignum propionicum</i>	63.03	1	1	1	1	1.136E7	47.4
Q9I3S1	Biofilm dispersion protein BdlA OS	<i>Pseudomonas aeruginosa</i>	59.07	22	1	1	1	3.282E7	46.9
B8J4A8	Sulfate adenylyltransferase OS	<i>Desulfovibrio desulfuricans</i>	210.65	1	5	5	5	2.656E7	46.9
A6L3M9	Enolase OS	<i>Bacteroides vulgatus</i>	48.62	2	1	2	2	3.004E7	46.7
Q043Z5	Enolase 1 OS	<i>Lactobacillus gasseri</i>	289.72	4	5	5	5	4.189E7	46.6
Q1ISS7	Enolase OS	<i>Koribacter versatilis</i>	71.57	4	1	1	1	7.884E6	46.5
B8DTI9	Enolase OS	<i>Bifidobacterium animalis</i> subsp. <i>lactis</i>	115.71	4	2	2	2	1.684E7	46.4
A7GUR7	Enolase OS	<i>Bacillus cytotoxicus</i>	122.68	17	2	2	3	2.771E7	46.4
Q2LR33	Enolase OS	<i>Syntrophus aciditrophicus</i>	31.73	1	1	1	1	4.823E7	46.2
Q89Z05	Enolase OS	<i>Bacteroides thetaiotaomicron</i>	140.16	2	2	4	5	3.005E7	46.1

B2RLL7	Enolase OS	Porphyromonas gingivalis	123.91	2	2	3	3	2.636E7	45.8
Q6MPQ2	Enolase OS	Bdellovibrio bacteriovorus	66.50	1	1	1	1	8.918E6	45.7
B0K742	Serine hydroxymethyltransferase OS	Thermoanaerobacter pseudethanolicus	85.67	92	2	2	2	2.140E7	45.6
Q5LFT7	Peptidase T OS	Bacteroides fragilis	89.56	5	1	1	1	7.323E7	45.5
A9NEA9	Serine hydroxymethyltransferase OS	Acholeplasma laidlawii	44.82	3	1	1	1	5.875E6	45.3
Q7MU77	Phosphoglycerate kinase OS	Porphyromonas gingivalis	54.70	1	1	1	1	2.106E7	45.0
Q8A753	Phosphoglycerate kinase OS	Bacteroides thetaiotaomicron	25.30	1	1	1	1	1.320E7	45.0
A5VHR0	Phosphopentomutase OS	Lactobacillus reuteri	159.08	1	4	4	4	4.364E7	44.0
A8EWM4	Phosphoglycerate kinase OS	Arcobacter butzleri	45.52	1	1	1	1	2.577E7	43.8
Q042T5	Elongation factor Tu OS	Lactobacillus gasseri	400.92	36	3	10	13	1.184E8	43.7
Q74JU6	Elongation factor Tu OS	Lactobacillus johnsonii	348.06	36	2	9	12	1.184E8	43.6
Q5L890	Elongation factor Tu OS	Bacteroides fragilis	185.88	297	3	5	7	1.454E8	43.6
Q8R603	Elongation factor Tu OS	Fusobacterium nucleatum subsp. nucleatum	150.02	302	1	3	3	6.170E7	43.4
B8J1A0	Elongation factor Tu OS	Desulfovibrio desulfuricans	139.50	64	2	3	3	4.287E7	43.4
A5VJ92	Elongation factor Tu OS	Lactobacillus reuteri	413.79	60	8	11	13	3.595E8	43.4

Note: *Score:* The Mascot score. *Proteins:* The total number of proteins contained in the protein group. *Unique Peptides:* The total number of peptides unique to the protein group. *Peptides:* The total number of peptides identified from all included searches for the master protein of the protein group. *PSMs:* The total number of peptide-spectrum matches identified from all included searches for the master protein of the protein group. *Area:* The chromatographic peak area was used to characterize the quantitative abundance of protein. *MW(kDa):* The theoretical molecular weight of the protein.

Table 3 Potential cross-reactive antigens identified in human fecal bacteria

NCBI Accession #	Protein Name	Bacterium	Score	Proteins	Unique Peptides	Peptides	PSMs	Area	MW [kDa]
A6LFK9	Polyribonucleotide nucleotidyltransferase OS	Parabacteroides distasonis	62.68	3	1	2	2	2.332E7	82.0
P75764	Uncharacterized protein YbhJ OS	Escherichia coli	27.35	1	1	1	1	3.198E7	81.5
Q8A4N6	Polyribonucleotide nucleotidyltransferase OS	Bacteroides thetaiotaomicron	226.97	23	6	7	7	6.947E7	78.3
B3DT30	Elongation factor G OS	Bifidobacterium longum	236.98	64	8	10	11	4.407E7	78.1
E1WNR6	Chaperone protein htpG OS	Bacteroides fragilis	131.15	4	1	2	2	4.992E7	77.9
O31673	ATP-dependent Clp protease ATP-binding subunit ClpE OS	Bacillus subtilis	120.19	73	1	3	4	8.448E7	77.9
A7ZSL5	Elongation factor G OS	Escherichia coli O139:H28	133.81	92	2	3	4	2.888E7	77.5
Q5L8A7	Elongation factor G OS	Bacteroides fragilis	431.35	187	3	10	14	1.391E8	77.5
A6KYJ7	Elongation factor G OS	Bacteroides vulgatus	361.61	186	2	9	12	1.342E8	77.4
A6LFP0	Methionine--tRNA ligase OS	Parabacteroides distasonis	65.86	8	1	1	1	4.772E7	77.4
P39396	Pyruvate/proton symporter BtsT OS	Escherichia coli	92.20	1	2	2	2	1.446E7	77.3
A9KNK6	Polyribonucleotide nucleotidyltransferase OS	Lachnoclostridium phytofermentans	68.87	1	1	1	1	1.075E8	76.9
Q5L6S5	Elongation factor G OS	Chlamydia abortus	76.05	58	1	2	3	1.622E7	76.8
Q67JU0	Elongation factor G OS	Symbiobacterium thermophilum	147.39	86	1	4	5	2.631E8	76.8
Q5U8S9	Elongation factor G OS	Staphylococcus intermedius	98.88	65	1	3	4	5.177E7	76.7
Q8A294	Putative K(+)-stimulated pyrophosphate-energized sodium pump OS	Bacteroides thetaiotaomicron	150.65	20	1	3	3	1.276E8	76.5
B9DYA6	Elongation factor G OS	Clostridium kluyveri	136.00	67	1	3	4	8.826E7	76.4
Q5WLR5	Elongation factor G OS	Bacillus clausii	134.85	81	1	4	5	1.119E8	76.4
Q97I51	Translation initiation factor IF-2 OS	Clostridium acetobutylicum	70.53	4	1	1	1	2.330E8	76.3
A0PXU3	Elongation factor G OS	Clostridium novyi	114.21	67	1	3	4	8.905E7	76.1
Q18CF4	Elongation factor G OS	Clostridioides difficile	174.49	59	1	4	5	1.288E8	75.8
Q8AB53	Putative glucosamine-6-phosphate deaminase-like protein BT_0258 OS	Bacteroides thetaiotaomicron	54.10	1	1	1	1	4.629E6	75.2
Q8XJ01	Penicillin-binding protein 1A OS	Clostridium perfringens	39.66	3	1	1	1	1.599E7	75.1
A6L7J7	Threonine--tRNA ligase OS	Bacteroides vulgatus	91.33	9	2	2	2	2.440E7	74.2
P30539	1,4-alpha-glucan branching enzyme GlgB OS	Butyrivibrio fibrisolvens	30.12	1	1	1	1	2.287E7	73.8
B2TIT5	Threonine--tRNA ligase OS	Clostridium botulinum	53.61	2	1	1	1	1.877E7	73.8

P56116	Chaperone protein HtpG OS	<i>Helicobacter pylori</i>	38.02	12	1	1	1	1.269E7	71.2
P0A9P7	ATP-dependent RNA helicase DeaD OS	<i>Escherichia coli</i> O6:H1	85.88	5	3	3	4	1.336E8	70.5
P19410	3-oxocholoyl-CoA 4-desaturase OS	<i>Clostridium scindens</i>	63.87	1	1	1	1	5.844E7	70.2
Q8RHJ2	Putative K(+)-stimulated pyrophosphate-energized sodium pump OS	<i>Fusobacterium nucleatum</i> subsp. <i>nucleatum</i>	140.41	23	1	3	3	1.320E8	68.9
A5CX56	Chaperone protein DnaK OS	<i>Vesicomysocius okutanii</i> subsp. <i>Calyptogena okutanii</i>	15.38	1	1	1	1	2.961E7	68.7
Q5LG30	Chaperone protein DnaK OS	<i>Bacteroides fragilis</i>	418.39	33	1	9	11	6.399E7	68.6
Q89YW6	Chaperone protein DnaK OS	<i>Bacteroides thetaiotaomicron</i>	372.24	35	1	7	9	6.399E7	68.3
A6L2X7	Chaperone protein DnaK OS	<i>Bacteroides vulgatus</i>	371.71	33	1	8	10	6.399E7	68.3
Q93GF1	Chaperone protein DnaK OS	<i>Prevotella loescheii</i>	185.46	1	4	4	4	3.512E7	68.0
A6LGR5	4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase (flavodoxin) OS	<i>Parabacteroides distasonis</i>	38.34	5	1	1	1	2.396E7	67.9
B8H444	ATP-dependent zinc metalloprotease FtsH OS	<i>Caulobacter vibrioides</i>	26.45	6	1	1	1	1.241E7	67.7
A9KIA6	Aspartate--tRNA(Asp/Asn) ligase OS	<i>Lachnoclostridium phytofermentans</i>	31.12	1	1	1	1	8.400E6	67.5
P0AG91	Protein translocase subunit SecD OS	<i>Escherichia coli</i> O157:H7	233.70	2	6	6	6	2.164E7	66.6
Q49Y22	Chaperone protein DnaK OS	<i>Staphylococcus saprophyticus</i> subsp. <i>saprophyticus</i>	56.64	206	1	2	2	1.171E7	66.5
A6LBU6	Aspartate--tRNA ligase OS	<i>Parabacteroides distasonis</i>	88.06	49	1	2	2	7.901E6	66.4
P21332	Oligo-1,6-glucosidase OS	<i>Bacillus cereus</i>	53.99	2	1	1	1	1.391E7	66.0
Q8A5W4	Lysine--tRNA ligase OS	<i>Bacteroides thetaiotaomicron</i>	154.84	2	2	2	2	1.304E7	65.9
Q8GBW6	Methylmalonyl-CoA carboxyltransferase 12S subunit OS	<i>Propionibacterium freudenreichii</i> subsp. <i>shermanii</i>	98.01	1	1	1	2	1.386E8	65.9
Q67S54	Chaperone protein DnaK OS	<i>Symbiobacterium thermophilum</i>	96.29	225	1	3	3	4.528E7	65.7
Q9RQ13	L-fucose isomerase OS	<i>Bacteroides thetaiotaomicron</i>	181.20	7	1	5	7	1.038E8	65.7
A6L048	L-fucose isomerase OS	<i>Bacteroides vulgatus</i>	162.35	5	2	6	7	3.672E7	65.6
Q56403	V-type ATP synthase alpha chain OS	<i>Thermus thermophilus</i>	132.50	30	1	1	2	1.117E7	63.6
Q8G7I6	Glucose-6-phosphate isomerase OS	<i>Bifidobacterium longum</i>	531.07	4	14	14	15	3.155E8	63.0
Q4JX51	Glucose-6-phosphate isomerase OS	<i>Corynebacterium jeikeium</i>	30.85	1	1	1	1	3.306E7	62.1
Q8FZC4	2-isopropylmalate synthase OS	<i>Brucella suis</i> biovar 1	51.65	8	1	1	1	1.014E7	61.6
A6TGT4	Glucose-6-phosphate isomerase OS	<i>Klebsiella pneumoniae</i> subsp. <i>pneumoniae</i>	53.60	21	1	1	1	3.337E7	61.3

P0AG69	30S ribosomal protein S1 OS	Escherichia coli O157:H7	88.52	1	2	2	2	8.393E6	61.1
Q9EZ02	Pyrophosphate--fructose 6-phosphate 1-phosphotransferase OS	Spirochaeta thermophila	110.07	2	2	2	2	1.245E8	61.0
O31716	Uncharacterized ABC transporter ATP-binding protein YkpA OS	Bacillus subtilis	48.45	1	1	1	1	2.259E6	61.0
P59173	Probable 2,3-bisphosphoglycerate-independent phosphoglycerate mutase OS	Leptospira interrogans serogroup Icterohaemorrhagiae serovar Lai	61.50	2	1	1	2	6.104E6	61.0
P23843	Periplasmic oligopeptide-binding protein OS	Escherichia coli	368.94	2	11	11	12	1.586E8	60.9
Q0SQ82	Formate--tetrahydrofolate ligase OS	Clostridium perfringens	167.47	26	1	3	4	6.063E7	60.4
P14407	Fumarate hydratase class I, anaerobic OS	Escherichia coli	66.46	4	2	2	2	4.922E7	60.1
Q3A9K2	Formate--tetrahydrofolate ligase OS	Carboxydotherrnus hydrogenofmans	110.68	55	1	3	3	3.356E8	60.1
Q251P8	Formate--tetrahydrofolate ligase 1 OS	Desulfitobacterium hafniense	72.85	55	1	2	2	5.742E8	60.0
C0QX38	Formate--tetrahydrofolate ligase OS	Brachyspira hyodysenteriae	145.04	9	1	2	3	2.562E7	60.0
Q189R2	Formate--tetrahydrofolate ligase OS	Clostridioides difficile	157.46	1	3	3	3	1.347E9	59.9
C4ZBG8	Formate--tetrahydrofolate ligase OS	Agathobacter rectalis	235.86	56	4	6	6	3.610E8	59.7
A8AQV7	Phosphoenolpyruvate carboxykinase (ATP) OS	Citrobacter koseri	104.30	44	4	5	5	1.300E8	59.6
Q24ZZ8	Formate--tetrahydrofolate ligase 2 OS	Desulfitobacterium hafniense	79.67	55	1	2	2	5.193E8	59.4
B2RHV8	Phosphoenolpyruvate carboxykinase (ATP) OS	Porphyromonas gingivalis	188.39	21	2	5	5	2.446E8	59.4
Q47VD0	Phosphoenolpyruvate carboxykinase (ATP) OS	Colwellia psychrerythraea	111.53	16	1	2	2	1.952E8	59.3
A1R7X2	Arginine--tRNA ligase OS	Paenarthrobacter aureus	43.93	15	1	1	1	2.994E7	59.2
Q8A414	Phosphoenolpyruvate carboxykinase (ATP) OS	Bacteroides thetaiotaomicron	293.03	21	3	8	8	3.939E8	59.1
C4ZBL1	Phosphoenolpyruvate carboxykinase (ATP) OS	Agathobacter rectalis	501.52	17	5	12	15	4.167E8	59.0
Q5L7N5	Phosphoenolpyruvate carboxykinase (ATP) OS	Bacteroides fragilis	420.91	17	1	6	12	2.103E8	59.0
A3CL27	Formate--tetrahydrofolate ligase 1 OS	Streptococcus sanguinis	145.32	20	1	2	3	3.296E7	59.0
A6LFQ4	Phosphoenolpyruvate carboxykinase (ATP) OS	Parabacteroides distasonis	438.19	17	5	11	14	2.336E8	58.9
C4ZAW6	Dihydroxy-acid dehydratase OS	Agathobacter rectalis	193.87	6	5	6	6	2.765E7	58.9
B9E299	Dihydroxy-acid dehydratase OS	Clostridium kluyveri	85.82	2	1	2	3	7.244E7	58.8
O09460	Phosphoenolpyruvate carboxykinase (ATP) OS	Anaerobiospirillum succiniciproducens	214.42	21	2	5	5	3.702E8	58.6
B2TIR2	Dihydroxy-acid dehydratase OS	Clostridium botulinum	46.21	2	1	1	1	3.131E6	58.5
B3DTV2	ATP synthase subunit alpha OS	Bifidobacterium longum	383.31	393	9	11	12	5.746E7	58.4
B3DRY6	Bifunctional purine biosynthesis protein PurH OS	Bifidobacterium longum	204.27	2	3	3	3	1.243E8	58.4
A6LIG0	60 kDa chaperonin OS	Parabacteroides distasonis	325.96	2	1	7	10	4.117E8	58.3

A5N857	Ribonuclease Y OS	Clostridium kluyveri	85.68	95	1	3	3	4.874E7	58.3
Q8G3N6	Inosine-5'-monophosphate dehydrogenase OS	Bifidobacterium longum	685.57	20	15	16	19	2.005E8	58.2
Q8A6P8	60 kDa chaperonin OS	Bacteroides thetaiotaomicron	591.81	1	2	11	15	2.794E8	58.2
Q5LAF6	60 kDa chaperonin OS	Bacteroides fragilis	690.75	1	4	15	20	5.301E8	58.2
A0Q2T1	60 kDa chaperonin OS	Clostridium novyi	58.42	6	2	2	2	2.212E8	58.1
A6KXA0	60 kDa chaperonin OS	Bacteroides vulgatus	948.24	1	11	22	26	6.146E8	58.1

Note: *Score:* The Mascot score. *Proteins:* The total number of proteins contained in the protein group. *Unique Peptides:* The total number of peptides unique to the protein group. *Peptides:* The total number of peptides identified from all included searches for the master protein of the protein group. *PSMs:* The total number of peptide-spectrum matches identified from all included searches for the master protein of the protein group. *Area:* The chromatographic peak area was used to characterize the quantitative abundance of protein. *MW(kDa):* The theoretical molecular weight of the protein.